Compare Paychex, Inc. (PAYX) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Paychex, Inc. trades at $104.29 (market cap $36.15B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.1× Paychex, Inc.'s market cap, and Paychex, Inc. pays the higher dividend (4.69%). Which is the better fit depends on your goals — on Pluang, investors hold Paychex, Inc. for 56 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| PAYX | REGN | |
|---|---|---|
Market Cap | $36.15B | $76.40B |
Volume | 2,429,537 | 626,381 |
Sector | Industrials | Health |
52-Week High | $128.59 | $852.03 |
52-Week Low | $85.57 | $557.73 |
Typical Hold Time | 56 Days | 107 Days |
Enterprise Value | $39.84B | $71.12B |
Dividend Yield | 4.69% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $104.46, up 3.41% today, but remains in a bearish technical trend with resistance near $103. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.34, and maintains robust profitability with a net margin of 27.35%. Recent news highlights concerns over labor market cooling and dividend sustainability despite consistent payouts.
Outlook is mixed: solid fundamentals and a $111 consensus price target suggest upside, but bearish technicals and competitive pressures pose risks. The stock offers income via dividends, yet investor sentiment is cautious amid earnings quality questions and macroeconomic headwinds affecting small business employment trends.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
